نتایج جستجو برای: enoxaparin

تعداد نتایج: 1833  

2014
Bennett Levitan Zhong Yuan Alexander GG Turpie Richard J Friedman Martin Homering Jesse A Berlin Scott D Berkowitz Rachel B Weinstein Peter M DiBattiste

PURPOSE Venous thromboembolism is a common complication after major orthopedic surgery. When prescribing anticoagulant prophylaxis, clinicians weigh the benefits of thromboprophylaxis against bleeding risk and other adverse events. Previous benefit-risk analyses of the REgulation of Coagulation in ORthopaedic surgery to prevent Deep vein thrombosis and pulmonary embolism (RECORD) randomized cli...

Journal: :Clinical therapeutics 2009
Sorrel E Wolowacz Neil S Roskell Fiona Maciver Stephen M Beard Paul A Robinson Jonathan M Plumb Gerry Dolan Ivan J Brenkel

OBJECTIVE This was an evaluation of the cost-effectiveness of oral dabigatran etexilate compared with subcutaneous low-molecular-weight heparin (enoxaparin) for the prevention of venous thromboembolism (VTE) after total knee replacement (TKR) and total hip replacement (THR) surgery from the perspective of the UK National Health Service. METHODS Dabigatran etexilate (220 mg once daily) was com...

Journal: :Reactions Weekly 2021

Journal: :Pediatrics 2014
Louis T Dang Jordan A Shavit Rani K Singh Sucheta M Joshi Steven M Leber John D E Barks Renée A Shellhaas

Low-molecular-weight heparins, such as enoxaparin, are often used to treat thrombosis in infants. We present 4 infants with diffuse brain injury who developed cerebral venous sinus thrombosis or deep vein thrombosis and were treated with enoxaparin. These infants subsequently developed subdural hemorrhages, and enoxaparin was stopped. In 3 cases, the subdural hemorrhages were found on routine s...

Journal: :Thrombosis research 2007
Roger C Carroll Robert M Craft Gregory L Whitaker Carolyn C Snider Ryan K Kirby Robert F Elder Mark D Hennessey

The anticoagulant effect of enoxaparin is readily observed by Thrombelastography (TEG), particularly on the reaction time (R) to form a clot, and is completely reversed by heparinase. In this study, recalcified citrated whole blood with heparinase (CNHR) and without (CNR), along with TEG R time, was used to derive a delta R (CNR-CNHR). This delta R (DeltaR) was then used to measure enoxaparin a...

2001
Véronique Mary Florence Wahl Jean - Marie Stutzmann

Background and Purpose—Heparin and heparinoids have long been proposed for stroke treatment. This study investigates the effect of enoxaparin (Lovenox, Clexane), a low-molecular-weight heparin, on functional outcome (neuroscore) and lesion size in stroke models with reversible and irreversible cerebral ischemia using middle cerebral artery occlusion (MCAO) in the rat. Methods—Ischemia was induc...

Journal: :The New England journal of medicine 2002
David Bergqvist Giancarlo Agnelli Alexander T Cohen Amiram Eldor Paul E Nilsson Anne Le Moigne-Amrani Flavia Dietrich-Neto

BACKGROUND Abdominal surgery for cancer carries a high risk of venous thromboembolism, but the optimal duration of postoperative thromboprophylaxis is unknown. METHODS We conducted a double-blind, multicenter trial in which patients undergoing planned curative open surgery for abdominal or pelvic cancer received enoxaparin (40 mg subcutaneously) daily for 6 to 10 days and were then randomly a...

2015
DANA HALES MAXIME CASTERAN ANNE SAPIN-MINET IOAN TOMUŢA MARCELA ACHIM LAURIAN VLASE PHILIPPE MAINCENT

BACKGROUND AND AIMS Recent studies have shown that low molecular weight heparins are effective in the treatment of inflammatory bowel disease. Therefore, there is considerable interest in the development of an oral colonic delivery pharmaceutical system allowing targeted release of heparin in the inflamed tissue. The objective of this study was to prepare microparticles for the oral administrat...

Journal: :Pharmacotherapy 2004
Bob L Lobo

In four randomized, controlled studies of patients undergoing orthopedic surgery, the antithrombotic efficacy and safety of subcutaneous fondaparinux 2.5 mg once/day were compared with those of subcutaneous enoxaparin regimens that were approved by the United States Food and Drug Administration. In patients undergoing elective hip replacement surgery, fondaparinux significantly reduced the freq...

Journal: :The Journal of invasive cardiology 2005
Erdal Cavusoglu Manish Lakhani Jonathan D Marmur

BACKGROUND The use of low-molecular weight heparin (LMWH) during percutaneous coronary intervention (PCI) has been limited by the presumed inability to monitor its anticoagulant effect using bedside assays. OBJECTIVES This study was designed to compare the dose-response of enoxaparin, dalteparin and unfractionated heparin (UFH) on the activated clotting time (ACT), and to determine whether th...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید